A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Pembrolizumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). In addition, the FDA has approved nivolumab, a PD-1 checkpoint inhibitor, in combination with chemotherapy as first line treatment for advanced or metastatic gastric/GEJ cancer. TST001 is a recombinant humanized monoclonal antibody against Claudin 18.2 (a tumor marker found in gastric/GEJ cancer. In this study, the combination therapy of chemotherapy or chemotherapy and pembrolizumab with and without TST001 could provide additional benefits to the management of these tumors.

开始日期2027-06-30

申办/合作机构

創勝醫藥集團有限公司

NCT04266730

/ Suspended临床1期

Phase I Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Administered Concurrently With Pembrolizumab

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

开始日期2027-05-20

申办/合作机构

Lineberger Comprehensive Cancer Center

NCT07843550

/ Not yet recruiting临床1/2期

A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy

This is a single-center, open-label Phase 1/2 trial evaluating the safety and efficacy of the combination of larotrectinib and pembrolizumab in patients with advanced/metastatic lung adenocarcinoma or melanoma.

开始日期2027-03-01

申办/合作机构

M.D. Anderson International España SA

100 项与帕博利珠单抗相关的临床结果

登录后查看更多信息

100 项与帕博利珠单抗相关的转化医学

登录后查看更多信息

100 项与帕博利珠单抗相关的专利（医药）

登录后查看更多信息

10,966

项与帕博利珠单抗相关的文献（医药）

2026-12-31·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

作者: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Shechtman, Yelena ; Lepage, Stéphanie ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Bélanger, Karl ; Jamal, Rahima ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States

Article

作者: Chafamo, Biruk ; Fernan, Catherine ; Muston, Dominic ; Qian, Feng ; Johnson, Geoffrey ; Tang, Yuexin ; Bensimon, Arielle G. ; Adkins, Douglas ; Zheng, Dandan ; Tzontcheva, Anjela ; Benjamin, Kimberly ; Uppaluri, Ravindra

AIMS:

In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-of-care [SOC] radiotherapy +/- cisplatin after surgery followed by pembrolizumab alone) significantly prolonged event-free survival vs. SOC alone, both in the intention-to-treat population and PD-L1 combined positive score (CPS) ≥1 subgroup. Perioperative pembrolizumab + SOC received Food and Drug Administration approval in June 2025 for resectable LA HNSCC expressing PD-L1 (CPS ≥ 1). The present study evaluated the cost-effectiveness of perioperative pembrolizumab + SOC versus SOC in this indication, from a US healthcare payer perspective.

MATERIALS AND METHODS:

A Markov cohort model with four states (event-free, local recurrence, incurable recurrence/progression, death) was developed to estimate lifetime costs, life years (LYs), and quality-adjusted LYs (QALYs) with 3% annual discounting. Transition probabilities were fitted to patient-level time-to-event data from KEYNOTE-689 through parametric multistate modelling. Costs of initial and subsequent treatment, adverse events, disease management, and terminal care were estimated in 2025$ based on trial results, drug labels, public databases, and literature. Utilities were derived through analyses of EQ-5D-5L data collected in KEYNOTE-689. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS:

Compared to SOC, perioperative pembrolizumab + SOC increased total costs by $82,311 and provided gains of 1.47 QALYs and 1.77 LYs. Incremental cost-effectiveness ratios of perioperative pembrolizumab + SOC vs. SOC were $55,863/QALY and $46,406/LY. Higher initial treatment costs of perioperative pembrolizumab (incurred mainly in Year 1) were partially offset by lower recurrence-related costs. At the typical $150,000/QALY threshold, perioperative pembrolizumab + SOC was cost-effective in 96% of probabilistic simulations.

LIMITATIONS:

Survival extrapolations beyond the available trial period are subject to uncertainty.

CONCLUSIONS:

Perioperative pembrolizumab + SOC was found to be cost-effective versus SOC for the treatment of resectable LA HNSCC with CPS ≥ 1.

20,449

项与帕博利珠单抗相关的新闻（医药）

9 小时之前

·BioSpace

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

SMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC Study Is Being Conducted in Collaboration with Summit’s Partner Akeso, with Clinical Trial Sites in the U.S. and China MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study (SMT112-216 / AK112-216 / NCT07877194 ) is being conducted in collaboration with Summit’s partner, Akeso Inc. SMT112-216 is a randomized, open-label Phase II clinical study designed to evaluate the safety and efficacy of multiple ivonescimab-based treatment approaches in patients with incurable locally advanced or metastatic ccRCC who have not received prior systemic therapy for advanced disease. The study plans to enroll approximately 100 patients at clinical trial sites in the U.S. and China. Participants will be randomized to receive ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or nivolumab plus ipilimumab as an established standard-of-care comparator regimen. Cadonilimab is an investigational PD-1 / CTLA-4 bispecific antibody developed by Akeso. This study is in addition to Summit’s clinical trial collaboration with Arcus Biosciences evaluating ivonescimab in combination with casdatifan, a HIF2α inhibitor, in a similar ccRCC setting. “In collaboration with Akeso, SMT112-216 reflects an important part of our shared strategy to evaluate ivonescimab across multiple treatment approaches, including combination regimens, in tumor types where meaningful unmet needs remain,” said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics. “As we continue to build a broad development program beyond lung, SMT112-216 adds to a growing body of studies in genitourinary and other malignancies that support our strategy to advance ivonescimab where there is strong scientific rationale.” “Ivonescimab’s dual targeting of PD-1 and VEGF is especially relevant in renal cell carcinoma, where both pathways have been shown to be valid targets to impact the course of the disease,” said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. “Evaluating multiple ivonescimab-based regimens in the treatment-naïve incurable setting gives us the opportunity to assess ivonescimab’s dual mechanism early in the treatment journey, where immune-based combinations are well established and a differentiated immuno-oncology approach could be meaningful for patients.” About Kidney Cancer According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,450 Americans will be diagnosed with kidney cancer in 2026. 1 ccRCC is the most common type of kidney cancer in adults. 2 If detected in its early stages, the five-year survival rate for kidney cancer is high; for patients with advanced or late-stage metastatic kidney cancer, however, the five-year survival rate is only 19%. 3 For metastatic kidney cancer, treatment options include immunotherapy-based combinations and targeted therapies. 4 About Ivonescimab Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF. This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al , iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab’s design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al , iScience, 2025) and increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets. Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso. There are currently 16 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, one of which is a multiregional study sponsored by a cooperative group, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC, commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3. In 2025, Summit began enrolling patients in HARMONi-7. Summit expanded its Phase III clinical development program into colorectal cancer (CRC) in the fourth quarter of 2025 by initiating enrollment in HARMONi-GI3. In 2026, Summit announced initiation of HARMONi-GU1, a Phase II/III study in urothelial carcinoma (bladder cancer) with global clinical trial site activations planned to begin by the fourth quarter of 2026. HARMONi is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI (e.g., osimertinib). Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization, which the FDA accepted for filing in January 2026; the Prescription Drug User Fee Act (PDUFA) goal date is November 14, 2026. HARMONi-3 is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression. The clinical trial is evaluating the two histologies as individual, separately powered cohorts with independent statistical powering. HARMONi-7 is a Phase III clinical trial evaluating ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression. HARMONi-GI3 is a Phase III clinical trial evaluating ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy in patients with first-line unresectable metastatic CRC. HARMONi-GU1 is a Phase II/III clinical trial evaluating ivonescimab plus the antibody drug conjugate (ADC) enfortumab vedotin (EV) compared to pembrolizumab plus EV as first-line therapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). ILLUMINE is a Phase III study being conducted by GORTEC, a cooperative group dedicated to Head and Neck Oncology, in recurrent / metastatic head and neck squamous cell carcinoma (r/m HNSCC). ILLUMINE is a three-arm Phase III clinical trial designed to evaluate ivonescimab monotherapy, as well as ivonescimab in combination with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal antibody, compared to monotherapy pembrolizumab in patients with PD-L1 positive r/m HNSCC. Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC, and one is in biliary tract cancer (BTC). In addition to Summit’s positive HARMONi study, Akeso has had positive read-outs in three single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, and HARMONi-6, for ivonescimab in NSCLC, including a statistically significant overall survival benefit in all three studies from China. Akeso has also reported a statistically significant OS benefit in the single-region (China), randomized Phase III HARMONi-GI1 trial in advanced BTC. HARMONi-A was a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR TKI. HARMONi-2 is a Phase III clinical trial evaluating monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression. HARMONi-6 is a Phase III clinical trial evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC, irrespective of PD-L1 expression. HARMONi-GI1 is a Phase III clinical trial evaluating ivonescimab in combination with chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced BTC. Akeso is actively conducting additional Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer. Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024. About Summit Therapeutics Inc. Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and the company’s shares are listed on the Nasdaq Global Market (symbol "SMMT"). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK. For more information, please visit and follow Summit on X @SMMT_TX. Summit Forward-Looking Statements Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the risk that the private placement does not close on the anticipated timeline or at all, including because required regulatory clearances are not obtained or other closing conditions are not satisfied, dilution to existing stockholders, and potential adverse effects on the market price of the Company's common stock, including from future sales by AstraZeneca, the Company's broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca’s ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company's reliance on AstraZeneca for the supply of AstraZeneca’s products and other contributions to the clinical trials, the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. References: American Cancer Society. Key Statistics About Kidney Cancer . Accessed October 12, 2026. American Cancer Society. What Is Kidney Cancer? . Accessed October 12, 2026. American Cancer Society. Survival Rates for Kidney Cancer . Accessed October 12, 2026. American Cancer Society. Targeted Drug Therapy for Kidney Cancer . Accessed October 12, 2026. Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved. Contacts Summit Therapeutics’ Media & Investor Contacts: Nathan LiaBraaten Senior Director, Investor Relations Tracy Jones Director, Media & Public Relations investors@smmttx.com media@smmttx.com

临床3期临床2期免疫疗法临床结果上市批准

9 小时之前

·BioSpace

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of patients in breast and lung cancer Additional analyses from two trials of raludotatug deruxtecan in ovarian cancer demonstrate emerging potential in gynecological cancers TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio with more than 30 abstracts, including four late breaking presentations, in multiple cancers at the 2026 European Society for Medical Oncology (#ESMO26) Congress. New data from six landmark trials demonstrate the company’s progress toward advancing new standards of care for patients in breast and lung cancer, including the DESTINY-Breast05 ( 539RO ), DESTINY-Breast06 ( 4279P ), DESTINY-Breast09 ( LBA49 ), DESTINY-Breast11 ( 543RO ) and DESTINY-Lung04 ( LBA74 ) phase 3 trials of Enhertu ® (trastuzumab deruxtecan) and the TROPION-Breast02 ( LBA96 ) phase 3 trial of Datroway ® (datopotamab deruxtecan). Additional data at ESMO also will spotlight the company’s commitment to advancing research for patients with advanced ovarian cancer across lines of therapy. An updated analysis, including progression-free survival and duration of response, will be presented from the REJOICE-Ovarian01 ( 1331P ) phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer. A mini oral presentation will highlight preliminary findings from the REJOICE-Ovarian02 ( 1247RO ) phase 1b/2 trial evaluating raludotatug deruxtecan in combination with bevacizumab in patients with platinum-resistant ovarian cancer. “The promising data for raludotatug deruxtecan in ovarian cancer and the robust scientific innovation demonstrated across our pipeline reflects our progress in advancing research for patients across multiple types of cancer,” said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. “Daiichi Sankyo continues to draw from its scientific and technological expertise to turn science into new medicines that can change the standard of care.” Data Demonstrate Benefit of DXd ADCs in Patients with Brain Metastases Research updates highlighting the impact of DXd ADCs in patients with brain metastases include late-breaking rapid oral and proffered paper presentations from the DESTINY-Breast09 ( LBA49 ) phase 3 trial evaluating Enhertu in combination with pertuzumab as a first-line treatment for patients with HER2 positive metastatic breast cancer and the TROPION-Breast02 ( LBA96 ) phase 3 trial evaluating Datroway as a first-line treatment for patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option. Final overall survival results of the TUXEDO-3 ( 690O ) phase 2 trial of patritumab deruxtecan (HER3-DXd) in patients with active brain metastases from metastatic breast cancer, advanced non-small cell lung cancer (NSCLC) or leptomeningeal disease from any solid tumor will be presented as a proffered paper. New Data and Trials-in-Progress Presentations Across DXd ADC Portfolio Additional data highlighting new research across the DXd ADC portfolio include oral and poster presentations, including final results of the TALENT ( LBA23 ) phase 2 trial of Enhertu alone or in combination with anastrozole, or in sequence with chemotherapy, as neoadjuvant treatment for patients with HR positive, HER2 low early stage breast cancer. New data in NSCLC include the NeoCOAST-2 ( 4244RO ) phase 2 trial reporting event-free survival results, as well as findings on the association of ctDNA clearance with clinical outcomes in patients with resectable, early stage NSCLC treated with a combination of Datroway plus durvalumab and chemotherapy, and a retrospective analysis evaluating mechanisms of insensitivity to the Datroway payload in subgroups of patients with advanced NSCLC in the TROPION-Lung01 ( 4451P ) phase 3 trial. Updated findings from the EPOC2003 ( 2888P ) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer: results from ESPERANZA ( 1014P ), an external comparator study evaluating Enhertu versus real-world standard of care as a second line or later treatment for patients with HER2 IHC 3+ solid tumors; and, the primary analysis evaluating patritumab deruxtecan monotherapy in patients with melanoma in the HERTHENA-PanTumor01 ( 2073RO ) phase 2 trial also will be presented. Trials-in-progress poster presentations include the DESTINY-Breast Guide ( 1795TiP ) prospective and interventional trial evaluating first-line treatment with Enhertu plus pertuzumab followed by palbociclib, endocrine therapy and dual HER2 blockade (trastuzumab plus pertuzumab), as well as retreatment with Enhertu following progression on maintenance therapy (palbociclib, endocrine therapy and trastuzumab plus pertuzumab) in previously untreated patients with HER2 positive advanced or metastatic breast cancer and the TROY ( 1335TiP ) phase 2 trial evaluating Enhertu in patients with recurrent ovarian cancer with disease progression on prior PARP inhibitor therapy. An overview of late-breaking, clinical data and trials-in-progress presentations from the ADC portfolio of Daiichi Sankyo includes: Presentation Title Author Abstract Presentation (CEST) LBAs Final results of TALENT: a neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer S. Hurvitz LBA23 Proffered Paper Presentation Friday, October 23 1:30 pm – 3:00 pm First-line datopotamab deruxtecan (Dato-DXd) vs. chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: exploratory analysis of patients with brain metastases in TROPION-Breast02 R. Dent LBA96 Proffered Paper Presentation Saturday, October 24 8:30 am – 10:00 am First-line trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant NSCLC: patient-reported outcomes from DESTINY-Lung04 S. Novello LBA74 Rapid Oral Presentation Saturday, October 24 8:30 am – 10:00 am DESTINY-Breast09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab vs taxane + trastuzumab + pertuzumab for patients with HER2+ advanced/metastatic breast cancer and baseline brain metastases C. Saura LBA49 Rapid Oral Presentation Monday, October 26 10:15 am – 11:45 am Breast DESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab vs. dose-dense doxorubicin + cyclophosphamide followed by THP in HER2+ early breast cancer J.F. Boileau 543RO Rapid Oral Presentation Friday, October 23 4:15 pm – 5:45 pm Patient-reported outcomes from DESTINY-Breast05: health-related quality of life with trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with high-risk HER2 positive early breast cancer C. Barrios 539RO Rapid Oral Presentation Friday, October 23 4:15 pm – 5:45 pm Paired-biopsy multi-omic analysis reveals target-independent mechanisms of antibody-drug conjugate resistance in metastatic breast cancer P. Tarantino 4449RO Rapid Oral Presentation Monday, October 26 10:15 am – 11:45 am Trastuzumab deruxtecan (T-DXd) vs. physician’s choice of chemotherapy in HR+, HER2 low metastatic breast cancer: a DESTINY-Breast06 ctDNA molecular response analysis G. Curigliano 4279P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm Trastuzumab deruxtecan (T-DXd) + pembrolizumab in previously treated human epidermal growth factor receptor 2-expressing advanced or metastatic breast cancer: primary analyses of the breast cohorts from the open-label, multicenter, phase 1b study DS8201-A-U106 H. Rugo 1771P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm DESTINY-Breast Respond HER2 low Europe non-interventional study of trastuzumab deruxtecan (T-DXd) in HER2 low metastatic breast cancer: update on baseline characteristics and anti-emetic treatment J.Y. Pierga 12P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Improving accuracy in HER2 ultralow identification: multi-site validation of an AI-decision support tool B. Van der Vegt 1784P Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Comparative evaluation of 7 artificial intelligence tools for HER2-low and ultralow scoring in breast cancer J.S. Frenel 287P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)-based therapy followed by palbociclib, endocrine therapy, and dual HER2 blockade in first-line human epidermal growth factor receptor positive, hormone receptor-positive advanced or metastatic breast cancer and retreatment with T-DXd (DESTINY-Breast Guide) S. Sammons 1795TiP Poster Presentation Saturday, October 24 12:00 pm – 12:45 pm Lung NeoCOAST-2: association of ctDNA clearance with clinical outcomes in a global platform phase 2 perioperative trial T. Cascone 4244RO Rapid Oral Presentation Sunday, October 25 8:30 am – 10:00 am Mechanisms of insensitivity to the datopotamab deruxtecan (Dato-DXd) payload in subgroups of patients with advanced non-small cell lung cancer in TROPION Lung01 N. Girard 4451P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: IDeate-Lung01 updated results M. Ahn 3842P Poster Presentation Monday, October 26 12:00 pm – 12:45 pm Ovarian Raludotatug deruxtecan (R-DXd) + bevacizumab in participants with platinum-resistant recurrent ovarian cancer: results for cohort B-1 of the phase 1b/2 REJOICE-Ovarian02 study A. Oaknin 1247RO Rapid Oral Presentation Saturday, October 24 08:30 am – 10:00 am Raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer: an updated analysis of efficacy and tolerability from the phase 2 part of REJOICE-Ovarian01 K. Hasegawa 1331P Poster Presentation Monday, October 26 12:00 pm – 12:45 pm A randomized phase 2, open-label, multicenter, study of trastuzumab deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14) J.Y. Lee 1335TiP Poster Presentation Monday, October 26 12:00 pm – 12:45 pm Gastric Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) vs ramucirumab plus paclitaxel in second-line treatment of patients with HER2+ unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma from DESTINY-Gastric04 M. Gumus 2925P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm Perioperative trastuzumab deruxtecan plus capecitabine and durvalumab in HER2 positive gastric or gastroesophageal junction cancer: a phase II study (EPOC2003) D. Takahari 2888P Poster Presentation Sunday, October 25 12:00 pm – 12:45 pm PanTumor Final results of the TUXEDO-3 phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases and leptomeningeal disease M. Preusser 690O Proffered Paper Presentation Sunday, October 25 10:15 am – 11:45 am Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: primary analysis from HERTHENA-PanTumor01 M. McKean 2073RO Rapid Oral Presentation Sunday, October 25 10:15 am – 11:45 am ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors F. Meric-Bernstam 1014P Poster Presentation Friday, October 23 3:15 pm – 4:00 pm About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of nine ADCs in clinical development crafted from ADC technology discovered in-house by Daiichi Sankyo. The DXd ADC Technology platform of Daiichi Sankyo consists of seven ADCs in clinical development where each ADC is comprised of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADCs include Enhertu and Datroway, which are being jointly developed and commercialized globally with AstraZeneca, and ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd) and patritumab deruxtecan (HER3-DXd), which are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939 and DS3790 are being developed by Daiichi Sankyo. Additional ADCs being developed by Daiichi Sankyo include DS3610, which consists of an antibody attached to a novel payload that acts as an agonist of STING, and DS1025, which consists of a CD25 directed antibody attached to an immuno-oncology optimized cytotoxic payload. Ifinatamab deruxtecan, raludotatug deruxtecan, patritumab deruxtecan, DS-3939, DS3610, DS3790 and DS1025 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established. About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit . Contacts MEDIA CONTACTS: Global: Jennifer Brennan Jennifer.brennan@daiichisankyo.com +1 908 900 3183 (mobile) Japan: DS-PR_jp@daiichisankyo.com INVESTOR RELATIONS CONTACT: DaiichiSankyoIR_jp@daiichisankyo.com

临床2期临床3期临床结果抗体药物偶联物免疫疗法

9 小时之前

·今日头条

ESMO Asia 2026｜瞭望前瞻，百余项中国胸部肿瘤领域研究闪耀狮城

ESMO Asia 2026｜瞭望前瞻，百余项中国胸部肿瘤领域研究闪耀狮城，不止参与，更是主角编者按： 2026年欧洲肿瘤内科学会亚洲年会（ESMO Asia 2026）将于2026年12月4日至6日在新加坡盛大召开。作为亚太地区规模最大、学术影响力最为深远的肿瘤学年度盛会之一，本届大会将汇聚来自亚太及全球各地的顶尖肿瘤学专家、科研人员与医疗保健提供者，旨在共同推动癌症研究进步、优化临床实践并全面提升患者诊疗水平。目前，ESMO官网已陆续公布大会详细日程及入选研究标题。值得高度关注的是，在本届大会已公布的研究中，中国学者主持开展的研究入选数量再创新高，表现极其亮眼。在备受瞩目的胸部肿瘤领域，共有9项研究成功入选口头报告（包含1项LBA、1项优选口头报告及7项快速口头报告），另有百余项研究入选壁报交流。这些研究内容全面覆盖了早期至晚期肺癌的靶向与免疫治疗、抗体偶联药物（ADC）研发、围手术期治疗，以及前沿的AI与多组学交叉研究等热门方向。《肿瘤瞭望》特结合大会最新日程，对胸部肿瘤领域中国学者入选的口头报告及壁报研究进行系统梳理，带您先睹为快！优选口头报告专题：胸部肿瘤日期：2026年12月4日时间：10:45 - 12:15 地点：Hall 406 摘要号：945O 英文标题：Benmelstobart plus anlotinib and chemotherapy versus standard chemoimmunotherapy in the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (L/M sq-NSCLC): A phase 3 study 中文标题：贝莫苏拜单抗联合安罗替尼+化疗对比标准化疗免疫治疗用于局部晚期/转移性鳞状非小细胞肺癌一线治疗：一项III期研究讲者：石远凯教授（中国医学科学院肿瘤医院）报告时间：10:45 - 10:55 摘要号：LBA8 英文标题：SYS6010 in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC: Interim analysis of SYNSTAR01 中文标题：SYS6010治疗EGFR-TKI耐药、EGFR突变的晚期非小细胞肺癌（NSCLC）：SYNSTAR01研究中期分析讲者：陆舜教授（上海交通大学医学院附属胸科医院）报告时间：10:55 - 11:05 快速口头报告专题：胸部肿瘤日期：2026年12月5日时间：09:00 - 10:30 地点：Hall 406 摘要号：895RO 英文标题：Neoadjuvant Furmonertinib Plus Platinum-Based Chemotherapy for Chinese Patients With Resectable EGFR-Mutated Non–Small Cell Lung Cancer (TD-FORESEE): A Single-arm, Multicentre, Phase 2 Trial 中文标题：伏美替尼联合含铂化疗新辅助治疗中国可切除EGFR突变非小细胞肺癌患者（TD-FORESEE）：一项单臂、多中心、2期临床试验讲者：段江南教授（空军军医大学唐都医院）报告时间：09:00 - 09:05 摘要号：946RO 英文标题：Vebreltinib Plus Andamertinib (PLB1004) vs Osimertinib as First-Line Treatment in EGFR-Mutant NSCLC with MET+: A Phase II Trial 中文标题：伯瑞替尼联合安达艾替尼 (PLB1004) 对比奥希替尼一线治疗伴MET阳性EGFR突变非小细胞肺癌：一项II期研究讲者：吴一龙教授（广东省人民医院）报告时间：09:10 - 09:15 摘要号：949RO 英文标题：First-line zongertinib in patients with advanced HER2-mutant NSCLC: updated results from Beamion LUNG-1 中文标题：宗艾替尼一线治疗晚期HER2突变非小细胞肺癌：Beamion LUNG-1 研究更新数据讲者：吴一龙教授（广东省人民医院）报告时间：09:48 - 09:53 专题：新药研发与精准医学日期：2026年12月6日时间：10:45 - 12:15 地点：Hall 407 摘要号：241RO 英文标题：Phase I/II Study of CVL006, A Novel Anti-PD-L1/VEGF Bispecific Antibody in Combination with Chemotherapy, ADCs Targeted Therapy for Patients with Advanced Solid Tumors 中文标题：新型抗PD-L1/VEGF双特异性抗体CVL006联合化疗、ADC靶向治疗晚期实体瘤患者的I/II期研究讲者：张力教授（中山大学肿瘤防治中心）报告时间：10:45 - 10:50 摘要号：246RO 英文标题：JSKN016, a First-in-Class TROP2/HER3 Bispecific Antibody–Drug Conjugate (ADC), in Pretreated Non-Small Cell Lung Cancer (NSCLC) with Rare/Uncommon Driver Genomic Alterations (DGAs) 中文标题：JSKN016（首创TROP2/HER3双特异性抗体偶联药物[ADC]）用于伴有罕见/少见驱动基因组变异（DGAs）的经治非小细胞肺癌（NSCLC）讲者：洪少东教授（中山大学肿瘤防治中心）报告时间：11:40 - 11:45 摘要号：248RO 英文标题：Phase I/II safety and efficacy of WSD0922-FU in non-small cell lung cancer patients harboring EGFR C797S mutations 中文标题：WSD0922-FU在携带EGFR C797S突变的非小细胞肺癌患者中的I/II期安全性与疗效讲者：周彩存教授（同济大学附属东方医院）报告时间：11:45 - 11:50 壁报专题：胸部肿瘤-早期日期：2026年12月4日摘要号：931eTiP 英文标题：Adjuvant Aumolertinib with or without Platinum-Based Chemotherapy for EGFR-Sensitive Mutant NSCLC with Co-Mutations in Stage II-IIIA: A Prospective Randomized Controlled Trial 中文标题：II-IIIA期伴共突变的EGFR敏感突变非小细胞肺癌（NSCLC）辅助阿美替尼联合或不联合含铂化疗：一项前瞻性随机对照试验讲者：Guoyu Zhang（河南科技大学第一附属医院）摘要号：929eP 英文标题：Cross-body-site microbial source-sink dynamics reveal a mobile microbiome assemblage in lung cancer 中文标题：跨部位微生物源-汇动力学揭示肺癌中存在可迁移的微生物群落讲者：王璐教授（上海市第十人民医院）摘要号：927P 英文标题：From Discovery to Clinical Implementation: DNA Methylation Biomarkers in Non-Small Cell Lung Cancer, 1999-2025 中文标题：从发现到临床转化：1999-2025年非小细胞肺癌（NSCLC）DNA甲基化生物标志物研究讲者：陈晨教授（中南大学湘雅二医院）摘要号：925P 英文标题：Mechanistic Study of the MYC/CTPS1/ATR Axis as a Targetable Therapeutic Vulnerability in MYC-Driven Lung Adenocarcinoma 中文标题：MYC/CTPS1/ATR轴作为MYC驱动肺腺癌可靶向治疗脆弱性的机制研究讲者：Jiayue Ye（浙江大学医学院附属第一医院）摘要号：923P 英文标题：First real-world experience of adjuvant lorlatinib in resected high-risk stage I ALK-positive non-small-cell lung cancer: feasibility and tolerability 中文标题：洛拉替尼辅助治疗手术切除后高危I期ALK阳性非小细胞肺癌（NSCLC）的首个真实世界经验：可行性与耐受性讲者：李富骊教授（广州医科大学附属第一医院）摘要号：922P 英文标题：Early Peripheral T-Lymphocyte Changes After Minimally Invasive Lung Cancer Surgery and Their Relation to the Extent of Lymph Node Dissection 中文标题：肺癌微创手术后早期外周T淋巴细胞变化及其与淋巴结清扫范围的关系讲者：Jieshuo Wang（广州医科大学附属第一医院）摘要号：921P 英文标题：Recurrence Gene Profiles of Adjuvant Osimertinib in Early-Stage EGFRm NSCLC: A Multicenter Real-World Study (RAISE) 中文标题：早期EGFR突变非小细胞肺癌（NSCLC）奥希替尼辅助治疗的复发基因谱：一项多中心真实世界研究（RAISE）讲者：张永昌教授（湖南省肿瘤医院）摘要号：919P 英文标题：Leveraging ctDNA-MRD for Prognostic Stratification, Adjuvant Therapy Guidance, and Multi-Dimensional Risk Model Construction in Postoperative Stage I-III NSCLC Patients 中文标题：利用ctDNA-MRD对I~III期术后非小细胞肺癌患者进行预后分层、辅助治疗指导及多维风险模型构建讲者：Xiling Shi（南京医科大学第一附属医院）摘要号：918P 英文标题：Prospective dynamic molecular residual disease analysis of perioperative nivolumab in resectable NSCLC: data from the CTONG1804 phase 2 clinical trial 中文标题：可切除非小细胞肺癌（NSCLC）围手术期纳武利尤单抗治疗的前瞻性动态分子残留病灶（MRD）分析：来自CTONG1804 II期临床试验的数据讲者：Wei-Chi Luo（广东省人民医院）摘要号：917P 英文标题：Aumolertinib as adjuvant therapy for patients with resected EGFR-mutated stage I NSCLC: A retrospective real-world study 中文标题：阿美替尼辅助治疗手术切除的I期EGFR突变非小细胞肺癌（NSCLC）：一项回顾性真实世界研究讲者：黄建源教授（福建省立医院）摘要号：916P 英文标题：Adjuvant therapy with anlotinib for non-pCR non-small cell lung cancer after neoadjuvant immunochemotherapy: A prospective study. 中文标题：新辅助免疫化疗后未达到病理完全缓解（non-pCR）的非小细胞肺癌（NSCLC）安罗替尼辅助治疗：一项前瞻性研究讲者：徐杰教授（天津市肿瘤医院）摘要号：915P 英文标题：PAXOS (China) - Adherence and Persistence to Adjuvant Osimertinib Among Patients with Early-stage Non-small Cell Lung Cancer (NSCLC): a Retrospective Observational Study 中文标题：PAXOS（中国）研究：早期非小细胞肺癌（NSCLC）患者奥希替尼辅助治疗的依从性与坚持用药情况：一项回顾性观察性研究讲者：Chenlei Zhang（辽宁省肿瘤医院）摘要号：914P 英文标题：Adjuvant Third-Generation EGFR-TKI Improves Relapse-Free Survival in Completely Resected Stage I Non-Small Cell Lung Cancer: A Multicenter Real-World Cohort Study 中文标题：第三代EGFR-TKI辅助治疗改善完全切除的I期非小细胞肺癌（NSCLC）无复发生存：一项多中心真实世界队列研究讲者：王龙飞教授（宁波大学附属第一医院）摘要号：913P 英文标题：Associations of oncogenic drivers with IASLC grade and spread through air spaces in resected non-mucinous lung adenocarcinoma 中文标题：手术切除的非黏液型肺腺癌中，驱动基因与IASLC分级及气腔播散（STAS）的相关性讲者：王利锋教授（重庆大学附属肿瘤医院）摘要号：911P 英文标题：Neoadjuvant lorlatinib in resectable stage IB-IIIB ALK-rearranged NSCLC: Simon stage 1 analysis of NEOLORA study 中文标题：可切除IB~IIIB期ALK重排非小细胞肺癌（NSCLC）的洛拉替尼新辅助治疗：NEOLORA研究的Simon 1期分析讲者：杨帆教授（北京大学人民医院）摘要号：910P 英文标题：Preserving lung function in the era of sublobar resection for early-stage lung cancer: three-month pulmonary function after wedge resection, segmentectomy, and lobectomy 中文标题：早期肺癌亚肺叶切除时代的肺功能保护：楔形切除、肺段切除与肺叶切除术后3个月肺功能比较讲者：Qicong Chen（中国，广州）摘要号：906P 英文标题：A Prospective Study on Artificial Intelligence guided Lung Cancer Screening for High-risk Never Smokers in Hong Kong: Baseline results of the LC-SHIELD study 中文标题：香港高危非吸烟人群人工智能（AI）辅助肺癌筛查的前瞻性研究：LC-SHIELD研究的基线结果讲者：Molly Li（香港中文大学）摘要号：904P 英文标题：An Interpretable Multi-Modal AI Framework Integrating 3D Deep Learning and Radiomics for Predicting Visceral Pleural Invasion in ≤3 cm Non-Small Cell Lung Cancer: A Retrospective Two-Centre Study 中文标题：整合3D深度学习与影像组学的可解释多模态AI框架用于预测≤3cm非小细胞肺癌（NSCLC）脏层胸膜侵犯：一项回顾性双中心研究讲者：Liqing Li（广西医科大学附属肿瘤医院）摘要号：903P 英文标题："Double Helix" Effects of Outdoor Air Pollution and Smoking on Lung Cancer Risk: Insights from Proteomic Analysis Based on a Large-Scale Prospective Population Cohort and Independent Real-World Validation 中文标题：室外空气污染与吸烟对肺癌风险的“双螺旋”效应：基于大型前瞻性人群队列及独立真实世界验证的蛋白质组学分析讲者：Yuxuan Liao（中国医学科学院肿瘤医院）摘要号：902P 英文标题：PLEDGE: A Pleura-Oriented, Tumor-Edge-Driven Multi-Evidence CT Framework for Preoperative Prediction of Visceral Pleural Invasion in Non-Small Cell Lung Cancer 中文标题：PLEDGE：一种面向胸膜、由肿瘤边缘驱动的多证据CT框架，用于术前预测非小细胞肺癌（NSCLC）脏层胸膜侵犯讲者：黄旭华教授（浙江大学医学院附属第一医院）摘要号：901P 英文标题：Injection-Tip-to-Thoracoscopic-Pleura Distance Predicts Fluorescence Intensity in CT-Guided ICG Localization of Pulmonary Nodules 中文标题：注射针尖至胸腔镜胸膜的距离可预测CT引导下ICG肺结节定位中的荧光强度讲者：Chen-Sung Lin（臺北醫學大學附設醫院）摘要号：898P 英文标题：From stage shift to mortality reduction: real-world evidence of lung adenocarcinoma screening in Taiwan, 2011–2023 中文标题：从分期前移到死亡率下降：2011-2023年中国台湾地区肺腺癌筛查的真实世界证据讲者：Ruru Chun-Ju Chiang（中国台湾大学公共卫生学院流行病学与预防医学研究所）摘要号：897P 英文标题：Incidence and Timing of Incident Lung-RADS ≥3 Nodules After Baseline-Negative LDCT in Health-Checkup Cohorts 中文标题：体检人群中基线低剂量CT（LDCT）阴性后新发Lung-RADS≥3类结节的发生率与发生时间讲者：Jingwen Diao（广州医科大学附属第一医院）摘要号：896P 英文标题：Integrative Tissue and Plasma Proteomics Reveals Molecular Features and Age-Related Differences in Early-Onset Lung Cancer 中文标题：组织与血浆整合蛋白质组学揭示早发性肺癌的分子特征及年龄相关差异讲者：Ruolin Gao（中国医学科学院肿瘤医院）专题：胸部肿瘤-局部晚期日期：2026年12月4日摘要号：YO23 英文标题：Tumor-informed ctDNA-MRD guided Postoperative Surveillance and Therapy Optimization in a HER2-Mutant Lung Adenocarcinoma patient 中文标题：基于肿瘤信息ctDNA-MRD指导HER2突变肺腺癌患者术后监测与治疗优化讲者：吴朝真教授（首都医科大学附属北京胸科医院）摘要号：YO22 英文标题：Induction Aumolertinib Reduces Target Volumes Enabling Definitive Radiotherapy and Durable PFS in Unresectable EGFR-Mutant NSCLC 中文标题：阿美替尼诱导治疗缩小靶病灶，使不可切除EGFR突变非小细胞肺癌（NSCLC）可接受根治性放疗并获得持久无进展生存讲者：Mengyun Liu（中国医学科学院肿瘤医院）摘要号：944eP 英文标题：Pathomics-Based Random Forest Modeling for Prediction of ALK Mutation Status in Non-Small Cell Lung Cancer 中文标题：基于病理组学的随机森林模型预测非小细胞肺癌（NSCLC）ALK突变状态讲者：Eva Yi Wah Cheung（香港大学）摘要号：942P 英文标题：RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-mutation Profiles, and Implications for Targeted and Immunotherapy 中文标题：RET融合阳性肺腺癌：不同融合伴侣对应的临床病理特征、共突变谱及靶向与免疫治疗启示讲者：Zihan Sun（中国医学科学院肿瘤医院）摘要号：941P 英文标题：Single-Cell Transcriptomics and In Silico Knockout Reveal ELK1 Involvement in Ferroptosis in Lung Adenocarcinoma 中文标题：单细胞转录组与计算机模拟敲除揭示ELK1参与肺腺癌铁死亡讲者：Zihao Li（浙江大学医学院附属第一医院）摘要号：940P 英文标题：Therapeutic differences associated with fusion partner heterogeneity in fusion-positive lung adenocarcinoma: a real-world cohort study 中文标题：融合阳性肺腺癌中融合伴侣异质性相关的治疗差异：一项真实世界队列研究讲者：Zihan Sun（中国医学科学院肿瘤医院）摘要号：939P 英文标题：Double-Dose Furmonertinib Retreatment After Resistance to EGFR-TKIs in Postoperative Recurrent Lung Adenocarcinoma: Efficacy and Impact of High-Risk Histological Patterns 中文标题：术后复发肺腺癌EGFR-TKI耐药后双倍剂量伏美替尼再治疗：疗效及高危组织学模式的影响讲者：Yucheng Ma（浙江大学医学院附属第一医院）摘要号：937P 英文标题：SLC40A1+ macrophages act as antigen-presenting cells in EGFR-mutant patients exhibiting resistance to tyrosine kinase inhibitors 中文标题：SLC40A1+巨噬细胞在酪氨酸激酶抑制剂（TKI）耐药的EGFR突变患者中充当抗原呈递细胞讲者：Shuxin Zhu（上海交通大学医学院附属胸科医院）摘要号：936P 英文标题：Efficacy and Safety of Serplulimab Plus Chemotherapy as First-Line Treatment for Pulmonary Neuroendocrine Neoplasms (PNENs): A Real-World Retrospective Study 中文标题：斯鲁利单抗联合化疗一线治疗肺神经内分泌肿瘤（PNENs）的疗效与安全性：一项真实世界回顾性研究讲者：江冠铭教授【南方医科大学第十附属医院（东莞市人民医院）】摘要号：935P 英文标题：Surgical and Survival Benefits of Neoadjuvant Targeted Therapy versus Chemoimmunotherapy in Lung Adenocarcinoma: A Dual-center Research 中文标题：肺腺癌新辅助靶向治疗对比新辅助免疫化疗的手术与生存获益：一项双中心研究讲者：Jiaxi Xu（中国医学科学院肿瘤医院）摘要号：934P 英文标题：High pathological response rate of neoadjuvant arterial infusion chemotherapy combined with immunotherapy in initially unresectable stage IIIB non-small cell lung cancer: an open-label, single-arm, phase II trial 中文标题：初始不可切除IIIB期非小细胞肺癌新辅助动脉灌注化疗联合免疫治疗的高病理缓解率：一项开放标签、单臂、II期临床试验讲者：马旭教授（同济大学附属上海市肺科医院）专题：胸部肿瘤-转移性日期：2026年12月4日摘要号：YO29 英文标题：Overcoming sequentially acquired furmonertinib resistance after third generation EGFR TKI: to target or not? 中文标题：第三代EGFR-TKI治疗耐药后合并对伏美替尼耐药：继续还是停用靶向治疗？讲者：张一辰教授（广东省人民医院）摘要号：YO28 英文标题：A Remarkable Salvage Response to Sacituzumab Tirumotecan in a Heavily treated, PD-L1-Negative KRAS G12C-Mutant Lung Adenocarcinoma patient 中文标题：经多线治疗，PD-L1阴性KRAS G12C突变肺腺癌患者，接受芦康沙妥珠单抗治疗获显著缓解讲者：盛舒言教授（首都医科大学附属北京胸科医院）摘要号：YO25 英文标题：Missed Truncal EGFR Exon 19del on Pleural Fluid NGS After Exceptional Chemo-IO Response: Long-Term Cerebrovascular Safety of Late-Line Almonertinib in High-Risk NSCLC 中文标题：化疗-免疫治疗获得超常缓解后，胸水NGS漏检主干EGFR外显子19缺失：后线阿美替尼治疗高危NSCLC的长期脑血管安全性讲者：Chenglin Xi（河北大学附属医院）摘要号：1042TiP 英文标题：A prospective, single-arm, phase II clinical trial of high-dose Aumolertinib combined with Ommaya reservoir chemotherapy and ventriculoperitoneal shunt in EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis 中文标题：高剂量阿美替尼联合Ommaya囊置管及脑室腹腔分流术治疗EGFR突变非小细胞肺癌伴脑膜转移的前瞻性单臂II期临床试验讲者：王素贞教授（山东省肿瘤医院）摘要号：1041eTiP 英文标题：Management strategy of 1L Lorlatinib with Hyperlipidemia in Stage IIIB-IV ALK positive NSCLC: A multi-center prospective study in China 中文标题：IIIB~IV期ALK阳性非小细胞肺癌一线洛拉替尼治疗相关高脂血症的管理策略：中国一项多中心前瞻性研究讲者：赵珅教授（中山大学肿瘤防治中心）摘要号：1040eTiP 英文标题：Aumolertinib combined with bevacizumab and pemetrexed as first-line treatment for EGFR-sensitive mutated NSCLC with brain or leptomeningeal metastases: An open-label, single-center, observational study 中文标题：阿美替尼联合贝伐珠单抗+培美曲塞一线治疗伴脑/软脑膜转移EGFR敏感突变非小细胞肺癌：一项开放标签单中心观察性研究讲者：Qichuan Wang（南阳市第二人民医院）摘要号：1039eTiP 英文标题：ctDNA Clearance-Guided Chemotherapy De-escalation in First-Line Aumolertinib-Based Regimen for Advanced EGFR-Mutant NSCLC: A Phase II, Single-Arm, Prospective Trial 中文标题：ctDNA清除指导下，阿美替尼一线方案的化疗降阶梯治疗晚期EGFR突变非小细胞肺癌：一项单臂前瞻性II期研究讲者：孟凡路教授（天津医科大学总医院）摘要号：1038eP 英文标题：The HIF-1α/METTL3/c-Myc Axis Promotes Vasculogenic Mimicry to Facilitate Malignant Progression in Non-Small Cell Lung Cancer 中文标题：HIF-1α/METTL3/c-Myc信号轴通过促进血管生成拟态推动非小细胞肺癌的恶性进展讲者：王琳教授（南京同仁医院）摘要号：1037eP 英文标题：LncRNA CHRM3-AS2 Reprograms Tumor-Associated Macrophages via Exosomal Delivery and PI3Kγ Ubiquitination to Suppress Lung Adenocarcinoma Progression 中文标题：LncRNA CHRM3-AS2通过外泌体传递及PI3Kγ泛素化重编程肿瘤相关巨噬细胞，从而抑制肺腺癌进展讲者：朱传东教授（南京市第二医院）摘要号：1035eP 英文标题：Prognosis Analysis in Oligometastatic NSCLC with Systemic Therapy and Iodine-125 Seed Implantation: A Retrospective Study 中文标题：全身治疗联合碘-125粒子植入治疗寡转移非小细胞肺癌（NSCLC）的预后分析：一项回顾性研究讲者：刘登尧教授（新疆医科大学第三临床医学院附属肿瘤医院）摘要号：1033eP 英文标题：Treatment Patterns, Patient Characteristics and Clinical Outcomes Among Patients with Transformed Small Cell Lung Cancer: A Systematic Literature Review 中文标题：转化性小细胞肺癌患者的治疗模式、患者特征与临床结局：系统文献综述讲者：杨志新教授（中国国立台湾大学肿瘤中心医院）摘要号：1029eP 英文标题：High-dose Furmonertinib in first-line treatment of patients with EGFR classically mutated advanced NSCLC 中文标题：高剂量伏美替尼一线治疗经典EGFR突变晚期非小细胞肺癌讲者：张路教授（华中科技大学同济医学院附属同济医院）摘要号：1025eP 英文标题：Atezolizumab (atezo) in patients (pts) with high PD-L1 1L stage IV NSCLC: a Phase III multicenter trial in China 中文标题：阿替利珠单抗一线治疗PD-L1高表达IV期非小细胞肺癌：一项中国多中心III期研究讲者：陆舜教授（上海交通大学医学院附属胸科医院）摘要号：1024eP 英文标题：Evaluating the Precision of 3D-Printing Template Technology in Iodine-125 Seed Implantation for Lung Metastases: A Retrospective Study. 中文标题：评估3D打印模板技术用于肺转移瘤碘-125粒子植入的精准度：一项回顾性研究讲者：刘登尧教授（新疆医科大学第三临床医学院附属肿瘤医院）摘要号：1023eP 英文标题：Real-world Efficacy and Safety of First-Line Third-Generation EGFR-TKI Combined with Chemotherapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer 中文标题：第三代EGFR-TKI联合化疗一线治疗晚期EGFR突变非小细胞肺癌的真实世界疗效与安全性讲者：Rongyu Zhang（山东大学齐鲁医院）摘要号：1020eP 英文标题：Beyond a fixed cut-off: gray-zone management of NGS-detected MET amplification in real-world NSCLC practice 中文标题：突破固定阈值：真实世界临床中NGS检出MET扩增灰区的管理策略讲者：Wei Rao（中国医学科学院肿瘤医院）摘要号：1019eP 英文标题：First-Line Toripalimab in Combination with Platinum-Doublet Chemotherapy for Advanced B3 Thymoma and Thymic Carcinoma: An Open-Label Prospective Phase II Trial 中文标题：特瑞普利单抗联合含铂双药化疗一线治疗晚期B3型胸腺瘤及胸腺癌：开放标签前瞻性II期研究讲者：胡兴胜教授（中国医学科学院肿瘤医院）摘要号：1018eP 英文标题：Efficacy and Safety of Recombinant Human Endostatin Combined with PD-1 Inhibitors in Previously Treated Advanced Squamous Non Small Cell Lung Cancer: A Prospective Single-Arm Study 中文标题：重组人血管内皮抑制素联合PD-1抑制剂治疗经治晚期肺鳞癌的疗效与安全性：一项前瞻性单臂研究讲者：糜磊教授（盐城市第一人民医院）摘要号：1017TiP 英文标题：Sacituzumab Tirumotecan Combined with Aumolertinib as First-Line Therapy in Patients with Advanced EGFR-Mutant NSCLC and High PD-L1 Expression 中文标题：芦康沙妥珠单抗联合阿美替尼一线治疗PD-L1高表达晚期EGFR突变非小细胞肺癌讲者：商琰红教授（河北大学附属医院）摘要号：1015TiP 英文标题：Implementation and independent benchmarking of a provenance-anchored AI harness for thoracic multidisciplinary team decision support 中文标题：基于溯源锚定的AI辅助胸部肿瘤多学科决策系统的落地与独立基准验证讲者：杨懿教授（成都市第三人民医院）摘要号：1013P 英文标题：Efficacy and Safety of Anematinib as First-Line Treatment in EGFR-Positive NSCLC Patients with Respiratory Comorbidities: A Retrospective Real-World Analysis 中文标题：阿美替尼一线治疗合并呼吸系统基础疾病EGFR阳性非小细胞肺癌的疗效与安全性：回顾性真实世界分析讲者：淦鑫教授（南昌大学第一附属医院）摘要号：1011P 英文标题：An AI-derived dynamic ctDNA framework for molecular response stratification in advanced NSCLC 中文标题：基于AI构建动态ctDNA模型用于晚期非小细胞肺癌分子疗效分层讲者：刘思阳教授（广东省人民医院）摘要号：1010P 英文标题：Matching-adjusted indirect comparison of unecritinib versus entrectinib in patients with ROS1-positive advanced non-small cell lung cancer 中文标题：Unecratinib对比恩曲替尼治疗ROS1阳性晚期非小细胞肺癌的匹配校正间接比较讲者：李子明教授（上海交通大学医学院附属胸科医院）摘要号：1009P 英文标题：Unecratinib versus crizotinib in ROS1-positive advanced non-small cell lung cancer: a matching-adjusted indirect comparison 中文标题：Unecratinib对比克唑替尼治疗ROS1阳性晚期非小细胞肺癌：匹配校正间接比较讲者：李子明教授（上海交通大学医学院附属胸科医院）摘要号：1007P 英文标题：Longitudinal peripheral blood immune profiling and treatment response prediction in patients with advanced non-small cell lung cancer receiving first-line immunotherapy 中文标题：接受一线免疫治疗的晚期非小细胞肺癌患者外周血免疫谱纵向检测及疗效预测讲者：Zimo Zhao（中国医科大学附属第一医院）摘要号：1005P 英文标题：Real-world rwPFS comparison of IAC, AC and IC regimens in advanced lung adenocarcinoma: A single-center retrospective cohort with IPTW and PSM adjustment 中文标题：IAC、AC、IC方案治疗晚期肺腺癌真实世界无进展生存期对比：经IPTW及PSM校正的单中心回顾队列讲者：李晓芳教授（河北大学附属医院）摘要号：1003P 英文标题：Combined Efficacy of Radioactive Iodine-125 Seed Brachytherapy and Radiofrequency Ablation for Thoracic Malignancies 中文标题：碘-125粒子近距离放疗联合射频消融治疗胸部恶性肿瘤的联合疗效讲者：刘登尧教授（新疆医科大学第三临床医学院附属肿瘤医院）摘要号：1002P 英文标题：Efficacy and Safety of Sacituzumab Tirumotecan in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer 中文标题：芦康沙妥珠单抗治疗晚期非鳞非小细胞肺癌的疗效与安全性讲者：秦海峰教授（解放军总医院）摘要号：1000P 英文标题：Comprehensive Multiomics Characterization of STK11/LKB1-Mutant Lung Cancer 中文标题：STK11/LKB1突变肺癌的多组学全景特征讲者：Zhengyang Yan（北京大学深圳医院）摘要号：999P 英文标题：Efficacy and safety of resencatinib (HS-10365) in patients with RET fusion-positive NSCLC: A pooled analysis 中文标题：Resencatinib (HS-10365)治疗RET融合阳性非小细胞肺癌的疗效与安全性：汇总分析讲者：周箴教授（上海交通大学医学院附属胸科医院）摘要号：998P 英文标题：First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy with or without Chemotherapy for Patients with MET-Altered Advanced Non-Small-Cell Lung Cancer: A Multicentre Retrospective Cohort Study 中文标题：MET改变晚期非小细胞肺癌一线MET-TKI对比免疫±化疗：一项多中心回顾性队列研究讲者：Shengling Hu（中国，成都）摘要号：996P 英文标题：Lorlatinib in ALK-positive advanced NSCLC: a real-world, multicenter study within a hub-and-spoke collaborative network across core and primary hospitals in China 中文标题：洛拉替尼治疗ALK阳性晚期非小细胞肺癌：中国核心医院与基层医院协同网络下的多中心真实世界研究讲者：邢镨元教授（中国医学科学院肿瘤医院）摘要号：994P 英文标题：Clinicopathologic Features of MTAP loss in advanced NSCLC with Actionable genomic alterations 中文标题：存在可靶向基因改变的晚期非小细胞肺癌中MTAP缺失的临床病理特征讲者：李安娜教授（广东省人民医院）摘要号：993P 英文标题：Association of Recombinant Zoster Vaccination With Reduced Mortality and Cardiopulmonary Events in Patients With Lung Cancer: A Real-World Propensity Score-Matched Study 中文标题：重组带状疱疹疫苗接种与肺癌患者死亡率及心肺事件下降相关：真实世界倾向评分匹配研究讲者：Shu-Farn Tey（中国台湾台南奇美医疗中心）摘要号：992P 英文标题：Prognostic Value of Intrathoracic Metastatic Patterns in M1b-M1c2 EGFR-Mutant Non-Small Cell Lung Cancer 中文标题：M1b-M1c2期EGFR突变非小细胞肺癌胸腔内转移模式的预后价值讲者：Yunchang Meng（四川大学华西医院）摘要号：991P 英文标题：Global trends in the management of first-line (1L) and second-line (2L) treatment in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): A real-world study 中文标题：全球EGFR突变晚期非小细胞肺癌一线、二线治疗模式变迁：一项真实世界研究讲者：钟华教授（上海交通大学医学院附属胸科医院）摘要号：990P 英文标题：Impact of Post-Resistance Molecular Retesting Strategies on Treatment Delivery and Clinical Outcomes After EGFR-TKI Resistance in Advanced EGFR-Mutant NSCLC: A Real-World Study 中文标题：EGFR-TKI耐药后再次分子检测策略对治疗方案及临床结局的影响：一项真实世界研究讲者：Wenting Zhang（福建医科大学福总临床医学院）摘要号：988P 英文标题：From clinical phenotype to metabolic vulnerability: multi-omics profiling of EGFR-TKI-associated brain metastases in EGFR-mutant NSCLC 中文标题：从临床表型到代谢弱点：EGFR突变非小细胞肺癌EGFR-TKI相关脑转移的多组学特征讲者：Xinyu Wang（中国医学科学院肿瘤医院）摘要号：985P 英文标题：Longitudinal single-cell profiling in EGFR-mutant NSCLC treated with osimertinib and sacituzumab tirumotecan 中文标题：奥希替尼联合芦康沙妥珠单抗治疗EGFR突变非小细胞肺癌的纵向单细胞谱分析讲者：Jingsong Cheng（中山大学肿瘤防治中心）摘要号：984P 英文标题：Aumolertinib in Combination with Radiotherapy for EGFR-Mutant Stage IV NSCLC with Oligoprogressive or Slow Progression: A Prospective Phase II Study 中文标题：阿美替尼联合放疗治疗伴寡进展/缓慢进展IV期EGFR突变非小细胞肺癌：一项前瞻性II期研究讲者：张莹莹教授（山东第一医科大学第一附属医院）摘要号：981P 英文标题：Impact of Radiofrequency Ablation on Disease Progression Patterns and CNS Metastasis Risk in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (ABLATE Study) 中文标题：射频消融对EGFR突变晚期非小细胞肺癌疾病进展模式及中枢转移风险的影响（ABLATE研究）讲者：生金教授（浙江大学医学院附属邵逸夫医院）摘要号：980P 英文标题：Patterns of first progression and CNS failure after aumolertinib in EGFR-mutant advanced NSCLC: a real-world cohort study 中文标题：EGFR突变晚期非小细胞肺癌阿美替尼治疗后首次进展模式及中枢进展：一项真实世界队列研究讲者：楚娴静教授（中南大学湘雅医院）摘要号：979P 英文标题：PD-L1 as a Negative Prognostic Biomarker and Positive Predictive Marker for Chemotherapy Intensification in EGFR-Mutant NSCLC: A Real-World Study 中文标题：PD-L1在EGFR突变非小细胞肺癌中作为负向预后标志物及化疗强化的阳性预测标志物：真实世界研究讲者：Xuewu Wei（广东省人民医院）摘要号：978P 英文标题：Serplulimab Combined with Bevacizumab and Chemotherapy in EGFR-TKI-Resistant Non-Squamous Non-Small Cell Lung Cancer with Brain Metastases: A Prospective, Multicenter, Single-Arm Study 中文标题：斯鲁利单抗联合贝伐珠单抗及化疗治疗EGFR-TKI耐药伴脑转移的非鳞非小细胞肺癌：一项前瞻性、多中心、单臂研究讲者：方申存教授（南京市胸科医院）摘要号：977P 英文标题：Treatment Patterns and Effectiveness of First-Line Osimertinib Combined with Diverse CTx in Chinese EGFR-Mutant NSCLC Patients with CNS Metastases: data from a Multicenter Prospective Real-World Study (FOREFRONT) 中文标题：中国伴中枢转移EGFR突变非小细胞肺癌一线奥希替尼联合不同化疗方案的治疗模式与疗效：多中心前瞻性真实世界FOREFRONT研究数据讲者：王启鸣教授（河南省肿瘤医院）摘要号：975P 英文标题：Andamertinib Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced NSCLC with Non-Classical EGFR Mutations: A Preliminary Analysis 中文标题：安达艾替尼联合铂类化疗一线治疗携带非经典EGFR突变晚期非小细胞肺癌：初步分析讲者：方文峰教授（中山大学肿瘤防治中心）摘要号：973P 英文标题：Firmonertinib plus 4 cycles platinum-pemetrexed as first-line treatment for EGFR-mutant locally advanced or metastatic NSCLC (FLAMES) 中文标题：伏美替尼联合4周期铂类+培美曲塞一线治疗EGFR突变局部晚期或转移性非小细胞肺癌（FLAMES研究）讲者：张乐蒙教授（湖南省肿瘤医院）摘要号：972P 英文标题：Third-generation EGFR mutation targeted drug-Osimertinib, Furmonertinib and Aumolertinib improved the prognosis of stage IV non-small-cell lung cancer 中文标题：第三代EGFR靶向药物奥希替尼、伏美替尼、阿美替尼改善IV期非小细胞肺癌患者预后讲者：Honghong Zhu【浙江中医药大学附属四省边际中医院（衢州市中医医院）】摘要号：971P 英文标题：Phase 1 Study of EGFR Degrader, BG-60366, in Previously Treated EGFR-Mutant Non-Small Cell Lung Cancer (EGFRmut NSCLC) 中文标题：EGFR降解剂BG-60366用于经治EGFR突变非小细胞肺癌的I期研究讲者：吴一龙教授（广东省人民医院）摘要号：970P 英文标题：Post-progression genomic landscapes following EGFR-TKI plus chemotherapy versus monotherapy in EGFR-mutant NSCLC 中文标题：EGFR突变非小细胞肺癌EGFR-TKI联合化疗对比单药治疗进展后的基因组特征讲者：Xiaohuan Zhou（广州医科大学附属第一医院）摘要号：969P 英文标题：Clinical and Molecular Characterizations Across Different PD-L1 Expression Classes in EGFR-Mutant NSCLC: A Real-World Study 中文标题：不同PD-L1表达水平EGFR突变非小细胞肺癌的临床与分子特征：一项真实世界研究讲者：Ran Huo（河北大学附属医院）摘要号：966P 英文标题：Vebreltinib in combination with firmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET amplification: Results from a phase Ib/II trial 中文标题：伯瑞替尼联合伏美替尼用于MET扩增的局部晚期/转移性EGFR突变非小细胞肺癌：Ib/II期研究结果讲者：张衍教授（四川大学华西医院肺癌）摘要号：961P 英文标题：A retrospective, multinational real-world study evaluating the effectiveness of Tarlatamab in patients with ES-SCLC treated under Expanded Access Programs in Korea and Taiwan 中文标题：塔拉妥单抗在韩国与中国台湾扩大使用项目中治疗广泛期小细胞肺癌疗效的多国回顾性真实世界研究讲者：Shang-gin Wu（中国国立台湾大学癌症中心）摘要号：960P 英文标题：Long-Term Follow-up of Overall Survival from Phase 2 Randomized Dose Optimization Study of Alveltamig (ZG006), a DLL3/DLL3/CD3 Trispecific T Cell Engager, as Monotherapy in Advanced Small Cell Lung Cancer 中文标题：DLL3/DLL3/CD3三特异性T细胞衔接剂Alveltamig (ZG006)单药治疗晚期小细胞肺癌II期随机剂量优化研究：总生存期长期随访结果讲者：艾星浩教授（上海交通大学医学院附属胸科医院）摘要号：959P 英文标题：Durvalumab+Anlotinib vs. Durvalumab monotherapy Maintenance in ES-SCLC: Final OS and Biomarker Analysis of Phase 2 DURABLE Trial 中文标题：度伐利尤单抗+安罗替尼对比度伐利尤单抗单药维持治疗广泛期小细胞肺癌：II期DURABLE研究最终OS及生物标志物分析讲者：韩宝惠教授（上海交通大学医学院附属胸科医院）摘要号：958P 英文标题：Efficacy and safety of sevabertinib in Chinese patients with HER2-mutant non-small cell lung cancer (NSCLC) in the SOHO-01 study 中文标题：SOHO-01研究：塞伐艾替尼治疗中国HER2突变非小细胞肺癌患者的疗效与安全性讲者：陆舜教授（上海交通大学医学院附属胸科医院）摘要号：957P 英文标题：Post-hoc Analysis of Squamous Subgroup from the CAMPASS Trial: Benmelstobart plus Anlotinib vs Pembrolizumab in First-Line PD-L1-Positive Advanced NSCLC 中文标题：CAMPASS研究鳞癌亚组事后分析：贝莫苏拜单抗+安罗替尼对比帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌讲者：韩宝惠教授（上海交通大学医学院附属胸科医院）摘要号：956P 英文标题：Tumor Response Dynamics of Atezolizumab plus Bevacizumab and Chemotherapy in the Asian Subgroup of the Phase III IMpower150 Trial 中文标题：III期IMpower150研究亚洲亚组：阿替利珠单抗+贝伐珠单抗+化疗的肿瘤应答动力学讲者：Wen-Chien Cheng（中国台湾中国医药大学附设医院）摘要号：955P 英文标题：First-Line Serplulimab-Based Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Prospective Real-World ASTRUM-002R Study 中文标题：基于斯鲁利单抗一线方案治疗局部晚期/转移性非小细胞肺癌：前瞻性真实世界ASTRUM-002R研究讲者：周建娅教授（浙江大学医学院附属第一医院）摘要号：954P 英文标题：Phase II Study of Serplulimab Plus Bevacizumab and Chemotherapy in Advanced Non-Squamous NSCLC Progressing on Prior Immunotherapy 中文标题：斯鲁利单抗+贝伐珠单抗+化疗用于免疫治疗进展后晚期非鳞非小细胞肺癌的II期研究讲者：常建华教授（中国医学科学院肿瘤医院深圳医院）摘要号：952P 英文标题：Efficacy and Safety of De-escalated First-line Immunotherapy Regimens in Older Patients with NSCLC: A Real-world Comparative Study 中文标题：降阶梯一线免疫治疗方案在老年非小细胞肺癌（NSCLC）患者中的疗效与安全性：一项真实世界对比研究讲者：陈华林教授（广东医科大学附属医院）专题：转化治疗 / 新药研发日期：2026年12月4日摘要号：277P 英文标题：Targeting the preserved CD2 axis improves the depth and durability of DLL3-directed T-cell engager therapy in small cell lung cancer 中文标题：靶向保留的CD2轴可提高靶向DLL3的T细胞衔接器（TCE）疗法在小细胞肺癌中的缓解深度与持久性讲者：褚倩教授（华中科技大学同济医学院附属同济医院）摘要号：276P 英文标题：Autophagic STING Degradation Drives Impaired Chemotherapy-Induced ICD in LKB1-mutant Lung Adenocarcinoma 中文标题：自噬介导的STING降解导致LKB1突变型肺腺癌中化疗诱导的免疫原性细胞死亡（ICD）受损讲者：Nan Jiang（浙江大学医学院附属第一医院）摘要号：273P 英文标题：Mechanistic investigation of PIM1-Mediated inhibition of CD8+T cell function and promotion of tumor immune escape 中文标题：PIM1介导抑制CD8+T细胞功能并促进肿瘤免疫逃逸的机制研究讲者：张宁教授（天津医科大学肿瘤医院）摘要号：260P 英文标题：Phase 1 Study of Bifunctional Anti-PD-1/IL-2 Fusion Protein AWT020 in Patients With Advanced Tumors 中文标题：双功能抗PD-1/IL-2融合蛋白AWT020治疗晚期肿瘤患者的1期研究讲者：陆舜教授（上海交通大学医学院附属胸科医院）摘要号：258P 英文标题：SIM01 Potentiates Anti-PD-L1 Therapy Through Microbiome and Immune Modulation in NSCLC 中文标题：SIM01通过调节微生物组与免疫微环境增强非小细胞肺癌（NSCLC）的抗PD-L1治疗疗效讲者：Tsz Tung Kwong（香港中文大学威尔斯亲王医院香港癌症研究所）内容来源：ESMO 官网 https://www.esmo.org/meeting-calendar/esmo-asia-congress-2026/programme 排名不分先后，按照摘要类别划分；如有遗漏或任何问题，请后台留言

100 项与帕博利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10574	帕博利珠单抗	L01FF02	DB09037

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
输卵管癌	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
非肌层浸润性膀胱肿瘤	澳大利亚	Merck Sharp & Dohme (Australia) Pty Ltd.	2026-07-23
浸润性膀胱癌	欧盟	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	冰岛	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	列支敦士登	Merck Sharp & Dohme BV	2026-07-01
浸润性膀胱癌	挪威	Merck Sharp & Dohme BV	2026-07-01
铂耐药性输卵管癌	中国	Merck Sharp & Dohme LLC	2026-06-23
铂类耐药性原发性腹膜癌	欧盟	Merck Sharp & Dohme BV	2026-04-22
铂类耐药性原发性腹膜癌	列支敦士登	Merck Sharp & Dohme BV	2026-04-22
铂耐药上皮性卵巢癌	欧盟	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	冰岛	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	列支敦士登	Merck & Co., Inc.	2026-04-02
铂耐药上皮性卵巢癌	挪威	Merck & Co., Inc.	2026-04-02
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme Corp.	2026-02-10
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肿瘤	美国	Merck Sharp & Dohme Corp.	2026-02-10
肿瘤	美国	Merck Sharp & Dohme LLC	2026-02-10
卵巢癌	美国	Merck Sharp & Dohme LLC	2026-02-10
卵巢癌	美国	Merck Sharp & Dohme Corp.	2026-02-10
肌层浸润性膀胱癌	美国	Merck Sharp & Dohme Corp.	2025-11-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性铂耐药性卵巢癌	申请上市	美国	Merck & Co., Inc.	2025-10-20
小肠癌	申请上市	欧盟	Merck Sharp & Dohme Corp.	2022-03-25
非小细胞肺癌Ⅰ期	临床3期	美国	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	日本	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	澳大利亚	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	巴西	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	加拿大	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	智利	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	哥伦比亚	Merck Sharp & Dohme LLC	2026-05-04
非小细胞肺癌Ⅰ期	临床3期	法国	Merck Sharp & Dohme LLC	2026-05-04

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02617849 (Pubmed \| Oncoimmunology)	临床2期	黑色素瘤	30	Pembrolizumab and Carboplatin/ Paclitaxel	餘膚鹹鹽衊積顧觸夢顧(遞鏇鹹願製鏇顧積齋鹹) = 壓淵築製醖襯淵廠襯獵觸淵醖鬱膚壓遞糧製願 (醖夢簾艱鑰鏇構範衊鬱 ) 更多	不佳	2026-12-31
ACR2026	N/A	肾细胞癌	27,394	ICI (RA)	製齋壓願構範襯願壓構(鹽醖淵顧鹹壓顧繭鏇範) = 範製壓遞壓積網憲顧範獵鑰網築蓋夢構蓋觸糧 (繭窪襯顧壓鬱獵壓衊積 ) 更多	积极	2026-11-06
				ICI (non-RA)	製齋壓願構範襯願壓構(鹽醖淵顧鹹壓顧繭鏇範) = 壓選願餘顧窪獵憲築繭獵鑰網築蓋夢構蓋觸糧 (繭窪襯顧壓鬱獵壓衊積 ) 更多
AASLD2026	N/A	不可切除的肝内胆管癌 TP53 mutations	41	gemcitabine, cisplatin, and durvalumab (GCD) or gemcitabine, cisplatin, and pembrolizumab (GCP)	憲餘鬱簾齋鏇壓願齋鹽(廠壓鹽構壓構餘觸網糧) = 夢鏇積積製選簾壓選獵齋獵鑰顧淵醖遞壓願網 (鬱遞蓋淵蓋憲廠餘鹹夢, 4.4 ~ 10.7) 更多	积极	2026-11-05
				gemcitabine, cisplatin, and durvalumab (GCD) or gemcitabine, cisplatin, and pembrolizumab (GCP) (TP53 wild-type ICC)	憲餘鬱簾齋鏇壓願齋鹽(壓艱鑰鹹膚廠糧願醖選) = 築夢鬱觸獵鏇積壓鹽選鬱鬱餘選壓鹽遞憲鏇積 (繭夢鏇蓋衊膚餘餘遞醖, 4.4 ~ 10.7) 更多
AASLD2026	临床2/3期	晚期胆道癌一线	3,000	Durvalumab + Gemcitabine + Cisplatin	衊糧壓簾夢鑰繭鑰鹽壓(襯夢餘淵鹽膚憲蓋窪顧): HR = 0.74 (95.0% CI, 0.63 ~ 0.87)	积极	2026-11-05
				Pembrolizumab + Gemcitabine + Cisplatin
NCT03598608 (MK-4280-003, Pubmed \| Blood Neoplasia)	临床1/2期	难治性经典霍奇金淋巴瘤 PD-1	34	Favezelimab 800 mg plus Pembrolizumab 200 mg	繭蓋醖築遞遞壓夢窪鏇(製繭構繭遞構糧獵顧選) = 1 of 21 participants experienced a dose-limiting toxicity (grade 4 autoimmune hepatitis) 蓋蓋簾淵築製糧簾餘廠 (醖遞膚蓋構淵窪壓鏇鏇 ) 更多	积极	2026-11-01
NCT04165083 (KEYMAKER-U01 substudy 01B \| KEYMAKER-U01B \| MK-3475-01B, CTgov)	临床2期	PD-L1阳性非小细胞肺癌	100	MK-4830+Pembrolizumab (MK-4830 + Pembrolizumab)	鏇構齋構簾憲齋鬱窪鑰 = 膚選觸積艱獵憲憲選襯顧顧顧糧醖襯鬱廠觸構 (構壓鹽憲壓鏇繭襯夢夢, 鏇襯蓋壓願憲鹹選艱廠 ~ 遞範齋簾鬱積網憲淵襯) 更多	-	2026-10-29
				MK-0482+Pembrolizumab (MK-0482 + Pembrolizumab)	鏇構齋構簾憲齋鬱窪鑰 = 製顧醖簾簾築範淵窪鬱顧顧顧糧醖襯鬱廠觸構 (構壓鹽憲壓鏇繭襯夢夢, 積網範製鬱築積鏇鹹艱 ~ 顧構選衊醖願願齋齋蓋) 更多
NCT04643379 (CTgov)	临床2期	转移性头颈部鳞状细胞癌 \| 复发性头颈部鳞状细胞癌	30	Peripheral blood draw+Olaparib+Carboplatin+Pembrolizumab	構餘繭夢廠鏇簾網夢糧 = 糧觸鬱獵觸網膚簾襯衊鬱願廠壓膚鑰鑰繭壓廠 (衊衊選鬱簾衊糧遞範簾, 獵淵鹹廠齋顧醖網鹽構 ~ 繭齋製簾顧壓鬱廠鬱遞) 更多	-	2026-10-27
ESMO2026	N/A	皮肤黑色素瘤辅助 \| 一线	370	Nivolumab or Pembrolizumab (weight-adjusted regimens)	鑰範鬱製鏇繭鹹範製膚(憲簾蓋積蓋選夢鬱糧遞) = 醖築網鑰糧範齋範願膚衊蓋膚築膚繭獵糧鏇鹽 (觸鏇選網襯憲糧鏇網淵, 60 ~ 81) 更多	积极	2026-10-23
				Nivolumab or Pembrolizumab (fixed-dose regimens)	鑰範鬱製鏇繭鹹範製膚(憲簾蓋積蓋選夢鬱糧遞) = 廠遞遞鬱積選簾蓋壓選衊蓋膚築膚繭獵糧鏇鹽 (觸鏇選網襯憲糧鏇網淵, 71 ~ 88) 更多
ESMO2026	N/A	头颈部鳞状细胞癌一线 \| 二线	34	PembrolizumabNivolumabumab + PembrolizumabNivolumabumab+chemotherapy + PembrolizumabNivolumab	遞築鏇鏇鹽窪蓋觸蓋構(衊醖艱選遞願網齋壓願) = 製憲鬱鹹廠廠淵鬱廠構壓積獵構膚襯蓋製願製 (衊獵範範窪鑰鹽膚範衊 ) 更多	积极	2026-10-23
NCT07523763 (ESMO2026)	临床2期	错配修复缺陷或微卫星高度不稳定性结直肠癌新辅助 dMMR \| MSI	30	Nivolumab 100 mg	醖築襯淵鹽醖簾網獵衊(製選艱艱顧遞窪範簾膚) = 獵壓壓襯築觸餘壓壓壓觸憲憲廠夢醖憲鏇遞憲 (鏇簾網餘衊築積鏇積構 ) 更多	积极	2026-10-23